0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative

0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Report 2023
Published Date: January 2023
|
Report Code: QYRE-Auto-17W2541
Home | Market Reports | Health| Health Conditions| Neurological Conditions
China Amyotrophic Lateral Sclerosis ALS Treatment Market Report Forecast 2021 2027
BUY CHAPTERS

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Research Report 2023

Code: QYRE-Auto-17W2541
Report
January 2023
Pages:83
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES

Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size

The global Amyotrophic Lateral Sclerosis (ALS) Treatment market was valued at US$ 326.4 million in 2022 and is anticipated to reach US$ 520.8 million by 2029, witnessing a CAGR of 8.1% during the forecast period 2023-2029.

Amyotrophic Lateral Sclerosis (ALS) Treatment Market

Amyotrophic Lateral Sclerosis (ALS) Treatment Market

Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
GlobalAmyotrophic Lateral Sclerosis (ALS) Treatment key players include Mitsubishi Tanabe Pharma, Sanofi, etc. Global top two manufacturers hold a share over 80%.
North America is the largest market, with a share about 60%, followed by Japan, and Europe, both have a share over 20 percent.
In terms of product, Edaravone (Radicava) is the largest segment, with a share over 75%. And in terms of application, the largest application is Hospital, followed by Drugs Store, etc.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (ALS) Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Amyotrophic Lateral Sclerosis (ALS) Treatment.
The Amyotrophic Lateral Sclerosis (ALS) Treatment market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Amyotrophic Lateral Sclerosis (ALS) Treatment market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Amyotrophic Lateral Sclerosis (ALS) Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.

Scope of Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report

Report Metric Details
Report Name Amyotrophic Lateral Sclerosis (ALS) Treatment Market
Accounted market size in 2022 US$ 326.4 million
Forecasted market size in 2029 US$ 520.8 million
CAGR 8.1%
Base Year 2022
Forecasted years 2023 - 2029
Segment by Type
  • Riluzole
  • Edaravone (Radicava)
  • Other
Segment by Application
  • Hospital
  • Drugs Store
  • Other
By Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia) Rest of Europe
  • Nordic Countries
  • Asia-Pacific (China, Japan, South Korea)
  • Southeast Asia (India, Australia)
  • Rest of Asia
  • Latin America (Mexico, Brazil)
  • Rest of Latin America
  • Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company Mitsubishi Tanabe Pharma, Sanofi, Mylan Pharma, Apotex, Glemark Generics, Covis Pharma, Sun Pharma, Lunan Pharma
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
  • Chapter 3: Detailed analysis of Amyotrophic Lateral Sclerosis (ALS) Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
  • Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
  • Chapter 12: The main points and conclusions of the report.

FAQ for this report

How fast is Amyotrophic Lateral Sclerosis (ALS) Treatment Market market growing?

Ans: The Amyotrophic Lateral Sclerosis (ALS) Treatment Market market witnessing a CAGR of 8.1% during the forecast period 2023-2029.

What is the Amyotrophic Lateral Sclerosis (ALS) Treatment Market market size in 2029?

Ans: The global Amyotrophic Lateral Sclerosis (ALS) Treatment market was valued at US$ 326.4 million in 2022 and is anticipated to reach US$ 520.8 million by 2029, witnessing a CAGR of 8.1% during the forecast period 2023-2029.

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Riluzole
1.2.3 Edaravone (Radicava)
1.2.4 Other
1.3 Market by Application
1.3.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Drugs Store
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Perspective (2018-2029)
2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Growth Trends by Region
2.2.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Region (2018-2023)
2.2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Region (2024-2029)
2.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Dynamics
2.3.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Industry Trends
2.3.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
2.3.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
2.3.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue
3.1.1 Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Revenue (2018-2023)
3.1.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Players (2018-2023)
3.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue
3.4 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio
3.4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in 2022
3.5 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Players Head office and Area Served
3.6 Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Product Solution and Service
3.7 Date of Enter into Amyotrophic Lateral Sclerosis (ALS) Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Type
4.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Type (2018-2023)
4.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2024-2029)
5 Amyotrophic Lateral Sclerosis (ALS) Treatment Breakdown Data by Application
5.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Historic Market Size by Application (2018-2023)
5.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2018-2029)
6.2 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2018-2023)
6.4 North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2018-2029)
7.2 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2018-2023)
7.4 Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2018-2029)
8.2 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2018-2023)
8.4 Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2018-2029)
9.2 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2018-2023)
9.4 Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (2018-2029)
10.2 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2018-2023)
10.4 Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Mitsubishi Tanabe Pharma
11.1.1 Mitsubishi Tanabe Pharma Company Detail
11.1.2 Mitsubishi Tanabe Pharma Business Overview
11.1.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.1.4 Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
11.1.5 Mitsubishi Tanabe Pharma Recent Development
11.2 Sanofi
11.2.1 Sanofi Company Detail
11.2.2 Sanofi Business Overview
11.2.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.2.4 Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
11.2.5 Sanofi Recent Development
11.3 Mylan Pharma
11.3.1 Mylan Pharma Company Detail
11.3.2 Mylan Pharma Business Overview
11.3.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.3.4 Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
11.3.5 Mylan Pharma Recent Development
11.4 Apotex
11.4.1 Apotex Company Detail
11.4.2 Apotex Business Overview
11.4.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.4.4 Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
11.4.5 Apotex Recent Development
11.5 Glemark Generics
11.5.1 Glemark Generics Company Detail
11.5.2 Glemark Generics Business Overview
11.5.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.5.4 Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
11.5.5 Glemark Generics Recent Development
11.6 Covis Pharma
11.6.1 Covis Pharma Company Detail
11.6.2 Covis Pharma Business Overview
11.6.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.6.4 Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
11.6.5 Covis Pharma Recent Development
11.7 Sun Pharma
11.7.1 Sun Pharma Company Detail
11.7.2 Sun Pharma Business Overview
11.7.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.7.4 Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
11.7.5 Sun Pharma Recent Development
11.8 Lunan Pharma
11.8.1 Lunan Pharma Company Detail
11.8.2 Lunan Pharma Business Overview
11.8.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Introduction
11.8.4 Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
11.8.5 Lunan Pharma Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
    Table 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
    Table 2. Key Players of Riluzole
    Table 3. Key Players of Edaravone (Radicava)
    Table 4. Key Players of Other
    Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
    Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2018-2023) & (US$ Million)
    Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2018-2023)
    Table 9. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
    Table 10. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2024-2029)
    Table 11. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends
    Table 12. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Drivers
    Table 13. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Challenges
    Table 14. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Restraints
    Table 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue by Players (2018-2023) & (US$ Million)
    Table 16. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Players (2018-2023)
    Table 17. Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment as of 2022)
    Table 18. Ranking of Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Companies by Revenue (US$ Million) in 2022
    Table 19. Global 5 Largest Players Market Share by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue (CR5 and HHI) & (2018-2023)
    Table 20. Key Players Headquarters and Area Served
    Table 21. Key Players Amyotrophic Lateral Sclerosis (ALS) Treatment Product Solution and Service
    Table 22. Date of Enter into Amyotrophic Lateral Sclerosis (ALS) Treatment Market
    Table 23. Mergers & Acquisitions, Expansion Plans
    Table 24. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Type (2018-2023) & (US$ Million)
    Table 25. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2018-2023)
    Table 26. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
    Table 27. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Type (2024-2029)
    Table 28. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Application (2018-2023) & (US$ Million)
    Table 29. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2018-2023)
    Table 30. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
    Table 31. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue Market Share by Application (2024-2029)
    Table 32. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 33. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 34. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 35. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 36. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 37. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 38. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
    Table 39. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2018-2023) & (US$ Million)
    Table 40. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Region (2024-2029) & (US$ Million)
    Table 41. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 42. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 43. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 44. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
    Table 45. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2018-2023) & (US$ Million)
    Table 46. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size by Country (2024-2029) & (US$ Million)
    Table 47. Mitsubishi Tanabe Pharma Company Detail
    Table 48. Mitsubishi Tanabe Pharma Business Overview
    Table 49. Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
    Table 50. Mitsubishi Tanabe Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023) & (US$ Million)
    Table 51. Mitsubishi Tanabe Pharma Recent Development
    Table 52. Sanofi Company Detail
    Table 53. Sanofi Business Overview
    Table 54. Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product
    Table 55. Sanofi Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023) & (US$ Million)
    Table 56. Sanofi Recent Development
    Table 57. Mylan Pharma Company Detail
    Table 58. Mylan Pharma Business Overview
    Table 59. Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
    Table 60. Mylan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023) & (US$ Million)
    Table 61. Mylan Pharma Recent Development
    Table 62. Apotex Company Detail
    Table 63. Apotex Business Overview
    Table 64. Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product
    Table 65. Apotex Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023) & (US$ Million)
    Table 66. Apotex Recent Development
    Table 67. Glemark Generics Company Detail
    Table 68. Glemark Generics Business Overview
    Table 69. Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product
    Table 70. Glemark Generics Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023) & (US$ Million)
    Table 71. Glemark Generics Recent Development
    Table 72. Covis Pharma Company Detail
    Table 73. Covis Pharma Business Overview
    Table 74. Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
    Table 75. Covis Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023) & (US$ Million)
    Table 76. Covis Pharma Recent Development
    Table 77. Sun Pharma Company Detail
    Table 78. Sun Pharma Business Overview
    Table 79. Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
    Table 80. Sun Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023) & (US$ Million)
    Table 81. Sun Pharma Recent Development
    Table 82. Lunan Pharma Company Detail
    Table 83. Lunan Pharma Business Overview
    Table 84. Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product
    Table 85. Lunan Pharma Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023) & (US$ Million)
    Table 86. Lunan Pharma Recent Development
    Table 87. Research Programs/Design for This Report
    Table 88. Key Data Information from Secondary Sources
    Table 89. Key Data Information from Primary Sources
List of Figures
    Figure 1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Comparison by Type (2023-2029) & (US$ Million)
    Figure 2. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Type: 2022 VS 2029
    Figure 3. Riluzole Features
    Figure 4. Edaravone (Radicava) Features
    Figure 5. Other Features
    Figure 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size Comparison by Application (2023-2029) & (US$ Million)
    Figure 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Application: 2022 VS 2029
    Figure 8. Hospital Case Studies
    Figure 9. Drugs Store Case Studies
    Figure 10. Other Case Studies
    Figure 11. Amyotrophic Lateral Sclerosis (ALS) Treatment Report Years Considered
    Figure 12. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
    Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
    Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region: 2022 VS 2029
    Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Players in 2022
    Figure 16. Global Top Amyotrophic Lateral Sclerosis (ALS) Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Amyotrophic Lateral Sclerosis (ALS) Treatment as of 2022)
    Figure 17. The Top 10 and 5 Players Market Share by Amyotrophic Lateral Sclerosis (ALS) Treatment Revenue in 2022
    Figure 18. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 19. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2018-2029)
    Figure 20. United States Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 21. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 22. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 23. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2018-2029)
    Figure 24. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 25. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 26. U.K. Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 27. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 28. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 29. Nordic Countries Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 30. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 31. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Region (2018-2029)
    Figure 32. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 33. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 34. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 35. Southeast Asia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 36. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 37. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 38. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 39. Latin America Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2018-2029)
    Figure 40. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 41. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 42. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 43. Middle East & Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market Share by Country (2018-2029)
    Figure 44. Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 45. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
    Figure 46. Mitsubishi Tanabe Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
    Figure 47. Sanofi Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
    Figure 48. Mylan Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
    Figure 49. Apotex Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
    Figure 50. Glemark Generics Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
    Figure 51. Covis Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
    Figure 52. Sun Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
    Figure 53. Lunan Pharma Revenue Growth Rate in Amyotrophic Lateral Sclerosis (ALS) Treatment Business (2018-2023)
    Figure 54. Bottom-up and Top-down Approaches for This Report
    Figure 55. Data Triangulation
    Figure 56. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)

OUR CUSTOMER

Nano Dimension

SIMILAR REPORTS

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

RELATED REPORTS

Global Spinal Muscular Atrophy Genetic Detection Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-14V5891
Tue Feb 20 00:00:00 UTC 2024

Add to Cart

Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-20D9534
Mon Feb 19 00:00:00 UTC 2024

Add to Cart

Global Diabetic Neurological Disorder Therapeutic Drug Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-10E13598
Mon Feb 19 00:00:00 UTC 2024

Add to Cart

Global Devic’s Syndrome (Neuromyelitis Optica) Treatment Market Research Report 2024

120 Pages
Type: Report
Code: QYRE-Auto-0Z7790
Thu Feb 08 00:00:00 UTC 2024

Add to Cart